ATE396742T1 - Komplexe mit adjuvanter wirkung - Google Patents

Komplexe mit adjuvanter wirkung

Info

Publication number
ATE396742T1
ATE396742T1 AT05701809T AT05701809T ATE396742T1 AT E396742 T1 ATE396742 T1 AT E396742T1 AT 05701809 T AT05701809 T AT 05701809T AT 05701809 T AT05701809 T AT 05701809T AT E396742 T1 ATE396742 T1 AT E396742T1
Authority
AT
Austria
Prior art keywords
complexes
cancer
substance
activity against
pharmacological activity
Prior art date
Application number
AT05701809T
Other languages
German (de)
English (en)
Inventor
Sunil Shaunak
Stephen Brocchini
Antony Godwin
Ji-Won Choi
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Application granted granted Critical
Publication of ATE396742T1 publication Critical patent/ATE396742T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05701809T 2004-01-07 2005-01-07 Komplexe mit adjuvanter wirkung ATE396742T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0400264.8A GB0400264D0 (en) 2004-01-07 2004-01-07 Complexes

Publications (1)

Publication Number Publication Date
ATE396742T1 true ATE396742T1 (de) 2008-06-15

Family

ID=31503533

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05701809T ATE396742T1 (de) 2004-01-07 2005-01-07 Komplexe mit adjuvanter wirkung

Country Status (10)

Country Link
US (1) US20090176866A1 (enExample)
EP (1) EP1701741B1 (enExample)
JP (1) JP2007518732A (enExample)
CN (1) CN1909928B (enExample)
AT (1) ATE396742T1 (enExample)
AU (1) AU2005203908B2 (enExample)
DE (1) DE602005007177D1 (enExample)
ES (1) ES2308432T3 (enExample)
GB (1) GB0400264D0 (enExample)
WO (1) WO2005065712A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
GB0722080D0 (en) * 2007-11-09 2007-12-19 Polytherics Ltd Novel complexes and a process for their preparation
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
WO2010003268A2 (en) 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
GB201210358D0 (en) * 2012-06-12 2012-07-25 Polytherics Ltd Complexes
BR112018076015A8 (pt) 2016-06-17 2022-06-28 Sanofi Pasteur Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
JP3180106B2 (ja) * 1990-10-24 2001-06-25 株式会社三和化学研究所 有機高分子化合物の製造方法
DE4337945A1 (de) * 1993-11-06 1995-05-11 Labtec Gmbh Pflaster zur Behandlung von Nagelmykosen
GB2290707A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of Amphotericin B
CA2299117A1 (en) * 1999-02-24 2000-08-24 Stiefel Research Institute, Inc. Antimycotic compositions
WO2001018080A1 (en) * 1999-09-08 2001-03-15 School Of Pharmacy, University Of London Uniform molecular weight polymers
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
AU2002258563A1 (en) * 2001-03-19 2002-10-03 Praecis Pharmaceuticals Incorporated Pharmaceutical formulations for sustained release
BR0105500A (pt) * 2001-11-05 2004-06-22 Univ Minas Gerais Processo de obtenção de dispersões coloidais de anfotericina b; composições à base de anfotericina b de uso enteral, parenteral e tópico; uso destas composições no tratamento de micoses sistêmicas e infecções parasitárias

Also Published As

Publication number Publication date
WO2005065712A2 (en) 2005-07-21
WO2005065712A3 (en) 2006-04-27
JP2007518732A (ja) 2007-07-12
AU2005203908A1 (en) 2005-07-21
EP1701741A2 (en) 2006-09-20
DE602005007177D1 (de) 2008-07-10
CN1909928B (zh) 2011-01-12
EP1701741B1 (en) 2008-05-28
ES2308432T3 (es) 2008-12-01
US20090176866A1 (en) 2009-07-09
CN1909928A (zh) 2007-02-07
AU2005203908B2 (en) 2011-02-03
GB0400264D0 (en) 2004-02-11

Similar Documents

Publication Publication Date Title
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
TR200103018T2 (tr) İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
CY1113984T1 (el) Προϊοντα συζευξης μεϋτανσινοειδους dm1 με αντισωμα trastuzumab, συνδεδεμενα μεσω μη-διασπασιμου συνδετηρα και χρηση αυτων στη θεραπεια ογκων
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
CY1119029T1 (el) Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
FI1897548T4 (fi) T-solujen säätely
CY1119906T1 (el) Πολυμερικες συζευξεις οπιοειδων ανταγωνιστων
NO20014491D0 (no) Fremgangsmåte
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
ATE478867T1 (de) Substituierte quinazolinone verbindungen
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
IS6667A (is) Aðferðir til að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4 sameind
EA201791843A2 (ru) Способы повышения эффективности folr1 терапии рака
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
CY1109692T1 (el) Νεες ανοσοδραστικες συνθεσεις
ATE546158T1 (de) Therapeutisches krebsmittel mit polymergebundenem antikörper
ATE396742T1 (de) Komplexe mit adjuvanter wirkung
WO2013104050A3 (en) Methods of treating triple negative breast cancer and basal-like breast cancer using inhibitors against kidney associated 1 (kaag1) inhibitor
BR0313588A (pt) Métodos para o tratamento da demência com base em apo e genótipo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties